Cargando…

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

AIM: To confirm the superiority, compared with placebo, of adding liraglutide to pre‐existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0–10.0% (53–86 mmol/mol)]. METHODS: In this 26‐week, double‐blind, parallel‐group st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054929/ https://www.ncbi.nlm.nih.gov/pubmed/26179619 http://dx.doi.org/10.1111/dom.12539

Ejemplares similares

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
por: DeVries, J. Hans, et al.
Publicado: (2012)

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
por: Nauck, Michael A, et al.
Publicado: (2018)

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
por: Rosenstock, J., et al.
Publicado: (2015)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
por: Barnett, A H
Publicado: (2012)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
por: Russell-Jones, D., et al.
Publicado: (2009)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
por: Marre, M, et al.
Publicado: (2009)

Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years
por: Mertes, Bernardo, et al.
Publicado: (2020)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia
por: Buturovic, Belma Ascic, et al.
Publicado: (2014)

Mood Predicts Response to Placebo CPAP
por: Stepnowsky, Carl J., et al.
Publicado: (2012)

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2
por: Ratner, R, et al.
Publicado: (2010)

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
por: Rodbard, Helena W, et al.
Publicado: (2018)

The metabolic and mitogenic properties of basal insulin analogues
por: Tennagels, Norbert, et al.
Publicado: (2013)

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
por: Bizino, Maurice B., et al.
Publicado: (2019)

The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
por: Gu, Jianqiu, et al.
Publicado: (2016)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial
por: van der Aa, M P, et al.
Publicado: (2016)

Correction to: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
por: Bizino, Maurice B., et al.
Publicado: (2019)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling
por: Chang, Ching-Chi, et al.
Publicado: (2018)

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
por: Parthsarathy, Vadivel, et al.
Publicado: (2013)

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
por: Tonoike, Mie, et al.
Publicado: (2018)

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity
por: Nexøe‐Larsen, Christina C., et al.
Publicado: (2018)

Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials
por: Zhong, Zhaoshuang, et al.
Publicado: (2021)

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Yan, Jinhua, et al.
Publicado: (2019)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (BEGIN: ADD TO GLP‐1 Study)
por: Aroda, V. R., et al.
Publicado: (2016)

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
por: Ratner, R E, et al.
Publicado: (2010)

Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure
por: Nauck, Michael A, et al.
Publicado: (2010)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)
por: Rodbard, Helena W., et al.
Publicado: (2017)

Effects of Metformin on the Regulation of Free Fatty Acids in Insulin Resistance: A Double-Blind, Placebo-Controlled Study
por: Castro Cabezas, Manuel, et al.
Publicado: (2012)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0o1k3qqkgtf8kf5ejr8egebb6u